Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Non-Randomized, Single-Center, Investigator-Initiated Trial to Determine the Effectiveness of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression

NCT06375564 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Xiamen University as lead sponsor.

NCT NCT06375564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06375564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Non-Randomized, Single-Center, Investigator-Initiated Trial to Determine the Effectiveness of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression
Lead sponsor
The First Affiliated Hospital of Xiamen University
Phase
Phase 1
Overall status
Recruiting
Start date
June 12, 2024
Completion date
December 30, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory solid tumor